PMID- 7929550
OWN - NLM
STAT- MEDLINE
DCOM- 19941027
LR  - 20161026
IS  - 0021-9509 (Print)
IS  - 0021-9509 (Linking)
VI  - 35
IP  - 4
DP  - 1994 Aug
TI  - Preoperative concurrent radiation therapy and cisplatinum continuous infusion in 
      IIIa (N2) non small cell lung cancer. A pilot study.
PG  - 341-6
AB  - From April 1991 to September 1993, 18 patients affected by a presumed operable 
      IIIa (N2) non small cell lung cancer (NSCLC) with histologically confirmed bulky 
      mediastinal metastases, received preoperative concurrent radiation therapy and 
      continuous infusion of cisplatinum (CDDP). The radiotherapy consisted of 2 Gy 
      given 5 days a week for a total dose of 50 Gy; CDDP was administered by means of 
      a central catheter and a portable pump at the daily dose of 6 mg/m2 given on the 
      same days as the radiation therapy (total dose: 150 mg/m2). Two weeks after the 
      end of the treatment, the patients were reevaluated: 5 patients had either local 
      or distant disease progression, the other 13 were submitted to thoracotomy: 12 
      received a complete resection and 1 patient underwent only a mediastinal 
      lymphadenectomy, because pneumonectomy was impossible due to lack of respiratory 
      function. No histological evidence of cancer cells was observed in the specimens 
      of 6 patients (33%). Radiological response rate was 61% (11/18); resection rate 
      was 66% (12/18) and complete resection rate was 61% (11/18). There was one 
      postoperative death (5%). The 3 year actuarial survival rate is 63.6% for the 
      patients who received a resection with a median survival time of 18 months. All 
      non operated patients died within one year. Combined preoperative treatment was 
      well tolerated. Better results were achieved in patients with squamous cell 
      carcinoma who had a complete resection following a total tumor sterilization with 
      radio-chemotherapy.
FAU - Maggi, G
AU  - Maggi G
AD  - Department of Thoracic Surgery, University of Turin, Italy.
FAU - Casadio, C
AU  - Casadio C
FAU - Cianci, R
AU  - Cianci R
FAU - Oliaro, A
AU  - Oliaro A
FAU - Molinatti, M
AU  - Molinatti M
FAU - Bretti, S
AU  - Bretti S
FAU - Clerico, M
AU  - Clerico M
FAU - Boidi-Trotti, A
AU  - Boidi-Trotti A
FAU - Rovea, P
AU  - Rovea P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Italy
TA  - J Cardiovasc Surg (Torino)
JT  - The Journal of cardiovascular surgery
JID - 0066127
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Actuarial Analysis
MH  - Adenocarcinoma/*drug therapy/mortality/pathology/*radiotherapy
MH  - Adult
MH  - Carcinoma, Large Cell/*drug therapy/mortality/pathology/*radiotherapy
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology/*radiotherapy
MH  - Carcinoma, Squamous Cell/*drug therapy/mortality/pathology/*radiotherapy
MH  - Cisplatin/*therapeutic use
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lung Neoplasms/*drug therapy/mortality/pathology/*radiotherapy
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pilot Projects
MH  - Preoperative Care/*methods
MH  - Prognosis
MH  - Radiotherapy Dosage
MH  - Survival Rate
MH  - Thoracotomy
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Surg (Torino). 1994 Aug;35(4):341-6.